YD Bio Ltd

YD Bio announced that its affiliate, EG BioMed US Inc., has secured out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania. This expansion extends the company's CLIA-certified, CAP-accredited laboratory's operating footprint to 46 U.S. states, Washington, D.C., and Guam, significantly broadening patient access for early cancer detection services. The new licenses reinforce YD Bio's transition to a platform-based biotechnology company and support its blood-based testing services for various cancers. The company also noted its ongoing non-binding Memorandum of Understanding to merge with EG BioMed, anticipated to close in 2026.

YD Bio reported full-year 2025 net revenue of $597K, a 17% increase, driven by expanded pharmaceutical sales and new product launches. The company posted a net loss of $8.3 million, significantly higher than the previous year, primarily due to increased operating expenses, including R&D and professional fees related to expansion. YD Bio strengthened its balance sheet with a business combination and a $13.2 million PIPE financing, ending the year with $6.0 million in cash. Strategic initiatives for 2026 include advancing its Limbal Stem Cell platform and OkaiDx™ Pancreatic Cancer Early Detection Program towards FDA submissions, and pursuing M&A, including a merger with EG BioMed.